BlaDimiR is a non-invasive molecular diagnostic platform based on the detection of a proprietary set of urinary biomarkers, specifically designed for bladder cancer. It uses the quantification of three microRNA (miRNA) profile systems and, in its most advanced version, also cytokines, to provide integrated solutions that enable early diagnosis (BlaDimiR), prediction of response to BCG immunotherapy (BlaDimiRplus), and prediction of response to combined BCG and anti-PD-L1 therapies (BlaDimiRIO). This precision technology facilitates more informed, personalized, and efficient clinical decision-making — without the need for invasive procedures.

Non-Invasive: BlaDimiR uses a simple urine sample.

High Accuracy: High sensitivity (90.5%) and specificity (97%), with a diagnostic accuracy of 96%.

Early Detection: Capable of detecting bladder cancer in its early stages, which is crucial for effective treatment. BlaDimiR has demonstrated a diagnostic accuracy of 96% in patients with a first-time suspicion of bladder cancer (incident cases) and 95% in patients with a previous history of bladder cancer who present new symptoms (recurrent cases).

Efficient Monitoring: Facilitates follow-up of patients who have already been treated, helping to detect recurrences early and in a less painful way.

Prediction of Treatment Response: BlaDimiRplus and BlaDimiRIO are “companion diagnostic” systems that enable prediction of the efficacy of BCG treatment or the combination of BCG with anti-PD-L1, allowing greater precision in selecting the best therapy for each patient and minimizing unnecessary side effects.